Organization (Hospital)
Vancouver Coastal Health
ClinicalTrials.gov lists Vancouver Coastal Health as lead sponsor of 23 trials, counting the companies grouped under it. Vancouver Coastal Health itself has 9 active development programs and 5 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 2 registered with a 2026 start date. The dashed outline is the pace from the 1 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 1.6 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Vancouver Coastal Health and 4 companies grouped under it: 23 lead-sponsored trials (9 its own, 14 in the grouped companies) and 5 legal-entity registrations (1 its own, 4 in the grouped companies).
Companies grouped under this page (4)
Shown in this order: most lead trials first.
| Company | Lead trials | Legal entities |
|---|---|---|
| Vancouver General Hospital | 9 | 1 |
| Lions Gate Hospital | 2 | 1 |
| Vancouver Coastal Health Research Institute | 2 | 1 |
| GF Strong Rehabilitation Centre | 1 | 1 |
Disease areas (154)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Pain | 8 |
| Spinal Cord Injuries | 8 |
| Diabetes Mellitus | 6 |
| Arthritis, Rheumatoid | 5 |
| Drug-Related Side Effects and Adverse Reactions | 4 |
Showing 5 of 154 disease areas.
Trials by start year as sponsor or collaborator (19)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2024 | 3 |
| 2023 | 3 |
| 2022 | 1 |
| 2021 | 4 |
| 2020 | 2 |
| 2019 | 1 |
| 2018 | 3 |
| 2017 | 2 |
| 2016 | 3 |
Showing 10 of 19 years.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (9)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Imipenem + Cilastatin | Mycobacterium Infections, Nontuberculous | Phase 1 | 1 |
| Mycobacteriophage Muddy_HRMN0052 | Mycobacterium Infections, Nontuberculous | Phase 1 | 1 |
| Amikacin Injection | Mycobacterium Infections, Nontuberculous | Phase 1 | 1 |
| Omadacycline Oral Tablet | Mycobacterium Infections, Nontuberculous | Phase 1 | 1 |
| Sulfamethoxazole trimethoprim | Mycobacterium Infections, Nontuberculous | Phase 1 | 1 |
Showing 5 of 9 active programs.
Approved assets (5)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Varenicline | 1 |
| Bedaquiline | 1 |
| Ceftaroline Fosamil | 1 |
| Clofazimine | 1 |
| LINEZOLID | 1 |
Journals published in (166)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| The New England journal of medicine | 9 |
| The Cochrane database of systematic reviews | 8 |
| Trials | 7 |
| Diabetes | 6 |
| JAMA | 6 |
Showing 5 of 166 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 1 | 0 | 1986-10-21 |
Organization relationships (42)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| University of British Columbia | Co sponsors trial with | 19 |
| University Health Network, Toronto | Co sponsors trial with | 5 |
| Arthritis Research Centre of Canada | Co sponsors trial with | 3 |
| Mount Sinai Health System | Co sponsors trial with | 2 |
| Centre Hospitalier de l’Université de Montréal | Co sponsors trial with | 2 |
Showing 5 of 42 relationships.
Latest dated events (121)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-11-02 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-08 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-04-29 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-03-30 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-01-11 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 121 events.
Biomarker capability evidence (39)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| CIC | Trial collaborator | Named in trial inclusion criteria |
| NADK | Trial collaborator | Named in trial inclusion criteria |
| NPPB | Trial collaborator | Named in trial inclusion criteria |
| OAT | Trial collaborator | Named in trial inclusion criteria |
| PDE5A | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 39 evidence rows.
Biomarkers this organization publishes on (347)
Shown in this order: most publications first.
Showing 5 of 347 biomarkers.
Not on this page
Checked, with nothing recorded for this organization: related companies not grouped here, sponsor delivery record, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.